Ligand-Based Discovery of a New Scaffold for Allosteric Modulation of the μ-Opioid Receptor

@article{Bisignano2015LigandBasedDO,
  title={Ligand-Based Discovery of a New Scaffold for Allosteric Modulation of the $\mu$-Opioid Receptor},
  author={Paola Bisignano and Neil T. Burford and Yi Shang and Brennica Marlow and Kathryn E. Livingston and Abigail M. Fenton and Kristin Rockwell and Lauren Budenholzer and John R. Traynor and Samuel W. Gerritz and Andrew Alt and Marta Filizola},
  journal={Journal of chemical information and modeling},
  year={2015},
  volume={55 9},
  pages={
          1836-43
        }
}
With the hope of discovering effective analgesics with fewer side effects, attention has recently shifted to allosteric modulators of the opioid receptors. In the past two years, the first chemotypes of positive or silent allosteric modulators (PAMs or SAMs, respectively) of μ- and δ-opioid receptor types have been reported in the literature. During a structure-guided lead optimization campaign with μ-PAMs BMS-986121 and BMS-986122 as starting compounds, we discovered a new chemotype that was… 

Figures and Tables from this paper

Pharmacologic Evidence for a Putative Conserved Allosteric Site on Opioid Receptors

Evidence is provided that B MS-986187 and BMS-986122 bind to a similar region on all three traditional opioid receptor types (µ-OR, δ- OR, and κ-OR).

Activation mechanism of the μ-opioid receptor by an allosteric modulator

NMR analyses of the μ-opioid receptor revealed that the MOR activity was determined by a conformational equilibrium between three conformations, and an allosteric modulator shifted the equilibrium toward a conformation with the highest activity to a level that cannot be reached by orthosteric ligands alone, leading to the increased activity of MOR.

Recent Advances in the Realm of Allosteric Modulators for Opioid Receptors for Future Therapeutics.

This review aims to explore recent developments in the structural motifs that potentiate orthosteric binding and their influences on cellular pathways in an effort to present novel approaches to opioid therapeutic design.

In Silico Insights on the Allosteric Modulation of the µ-Opioid Receptor and G Protein Complex in the Presence of Agonist Ligand BU72 and Potential Positive Allosteric Modulator BMS-986121

Rationalization of allosteric modulation in µ-opioid receptor-G protein complex may improve drug discovery schemes and strategies for allosterics drugs including other targets in the GPCR protein families.

Novel Positive Allosteric Modulators of µ Opioid Receptor—Insight from In Silico and In Vivo Studies

Analysis of molecular dynamics simulations in silico and ‘writhing’ tests in vivo suggest that investigated compounds bind to μ opioid receptor in an allosteric site, augmenting action of morphine at subeffective doses, and exerting antinociceptive effect alone at higher doses.

Measuring ligand efficacy at the mu-opioid receptor using a conformational biosensor

This work presents a direct way to quantify the efficacy of ligands by measuring the binding of a R*-specific biosensor to purified receptor employing interferometry and demonstrates that the technique can be utilized with heterotrimeric G protein.

Allostery at opioid receptors: modulation with small molecule ligands

The rationale and promise for the development of allosteric modulators for opioid receptors, the discovery of selective allosterIC modulators, the identification of potential allosterics sites on opioid receptors and the mode of action of the modulators are described.

Emerging Insights into Mu Opioid Pharmacology.

This chapter reviews recent advances in developing novel opioid analgesics from an understanding of mu receptor structure and function and highlights the development of novel agonist mechanisms, including biased agonists, bivalent ligands, and allosteric modulators of mu receptors function.

Utilization of Biased G Protein-Coupled Receptor Signaling towards Development of Safer and Personalized Therapeutics

Recognizing specific downstream signaling pathways can be enriched while those that bring unwanted side effects can be prevented on a patient-specific basis will improve studies that centered on development of safer and personalized therapeutics, thus alleviating the burden on economy and public health.

References

SHOWING 1-10 OF 18 REFERENCES

Structural insights into μ-opioid receptor activation

A 2.1 Å X-ray crystal structure of the murine μOR bound to the morphinan agonist BU72 and a G protein mimetic camelid antibody fragment is reported, revealing an extensive polar network between the ligand-binding pocket and the cytoplasmic domains appears to play a similar role in signal propagation for all three G-protein-coupled receptors.

Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor

Positive allosteric modulators (PAMs) can also have the specific advantage of only modulating the activity of the receptor when the orthosteric agonist occupies the receptor, thus maintaining spatial and temporal control of receptor signaling in vivo.

Crystal structure of the μ-opioid receptor bound to a morphinan antagonist

The 2.8 Å crystal structure of the mouse µ-OR in complex with an irreversible morphinan antagonist is described, revealing high-resolution insights into opioid receptor structure that will enable the application of structure-based approaches to develop better drugs for the management of pain and addiction.

Discovery, synthesis, and molecular pharmacology of selective positive allosteric modulators of the δ-opioid receptor.

These δ PAMs increase the affinity and/or efficacy of the orthosteric agonists leu-enkephalin, SNC80 and TAN67, as measured by receptor binding, G protein activation, β-arrestin recruitment, adenylyl cyclase inhibition, and extracellular signal-regulated kinases activation.

Novel GPCR paradigms at the μ‐opioid receptor

The progress, to date, towards identification and quantification of biased agonism and allosterism at the μ‐opioid receptor is examined in the context of its implications for the discovery of better and safer analgesics.

Positive allosteric modulators of the μ‐opioid receptor: a novel approach for future pain medications

The potential advantages that a μ‐PAM approach might bring to the design of novel therapeutics for pain that may lack the side effects currently associated with opioid therapy are described.

Identification of Selective Agonists and Positive Allosteric Modulators for µ- and δ-Opioid Receptors from a Single High-Throughput Screen

A 1536-well high-throughput screen of over 1 million compounds was developed and executed to detect potential hetero-oligomer selective ligands using a β-arrestin recruitment assay in U2OS cells coexpressing recombinant µ- and δ-opioid receptors.

The µ opioid receptor and ligands acting at the µ opioid receptor, as therapeutics and potential therapeutics.

The crystal structure of the MOR available today will enable the application of structure-based approaches to design better drugs for the management of pain, addiction and other human diseases, where MORs play a key role.

Disruption of the Na+ ion binding site as a mechanism for positive allosteric modulation of the mu-opioid receptor

It is demonstrated that PAM activity at MOPr allosterically disrupts Na+ binding, thereby forming an active-state receptor, and disruption of the Na+ ion binding site may represent a common mechanism for allosteric modulation of class A GPCRs.